Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 1 3Phase 2 1Phase 1/2 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 56Rectal Neoplasms 30Colonic Neoplasms 29Pancreatic Neoplasms 27Neoplasms 20Neoplasm Metastasis 18Stomach Neoplasms 17Carcinoma, Non-Small-Cell Lung 14Unspecified Adult Solid Tumor, Protocol Specific 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Myeloid, Acute 8Esophageal Neoplasms 8Ovarian Neoplasms 7Lymphoma, Non-Hodgkin 7Lymphoma 7Adenocarcinoma 7Myelodysplastic Syndromes 6Lung Neoplasms 6Gallbladder Neoplasms 6Breast Neoplasms 6Sarcoma 5Osteosarcoma 5Liver Neoplasms 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hodgkin Disease 5Carcinoma, Renal Cell 5Carcinoma, Hepatocellular 5Bile Duct Neoplasms 5Triple Negative Breast Neoplasms 4Solid Tumor 4

Interventions

Fluorouracil 4Paclitaxel 3Leucovorin 3Irinotecan 3napabucasin 2entinostat 2Gemcitabine 2Bevacizumab 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2spartalizumab 1ribociclib 1pembrolizumab 1palbociclib 1olaparib 1irinotecan sucrosofate 1huachansu 1guadecitabine 1fludarabine 1ficlatuzumab 1dostarlimab 1Taxes 1Stem Cell Transplantation 1Sorafenib 1Sirolimus 1Ramucirumab 1Oxaliplatin 1Nivolumab 1Melphalan 1Lutetium-177 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Digestive System Neoplasms × Leucovorin × Clear all
NCT02231723 2023-11-18

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer

Sumitomo Pharma America, Inc.

Phase 1 Completed
139 enrolled
Gastrointestinal

Pancreatic cancer, adult, Digestive System Neoplasms, Endocrine Gland Neoplasms, Adenoma, Islet Cell, Pancreatic Diseases, Pancreatic Neoplasms, Carcinoma, Islet Cell, Carcinoma, Pancreatic Ductal

NCT04299880 2023-11-08

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Sumitomo Pharma America, Inc.

Phase 1 Completed
7 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms

NCT01434069 2015-12-24

Phase I Trial of Combination of FOLFIRI and SOM 230

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
16 enrolled
Gastrointestinal

Digestive System Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡